General (152) Partnerships (43) New Products (9) Acquisitions (6) New Technologies (5) Financials (3)
Pharma and Biotech (167) Corporate (25) Bioscience (8)
2021 (8) 2020 (42) 2019 (29) 2018 (23) 2017 (21) 2016 (26) 2015 (12) 2014 (6)
English (167)
EnglishX
Showing 41‐60 of 167
results per page
18 May 2020
Moncef Slaoui to Step Down as Member of the Board of Directors of Lonza Group
Basel, Switzerland, 18 May 2020 – Dr Moncef Slaoui has decided to step down from his position as a member of the Lonza Group Board of Directors,...
12 May 2020
Noga Therapeutics and Lonza Announce Collaboration to Develop Autologous Lentiviral Gene Therapy on the Cocoon Platform
Collaboration between Noga Therapeutics and Lonza will leverage the innovative Cocoon® Platform for a novel primary immunodeficiency (PID)...
01 May 2020
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
•  Collaboration goal to enable manufacturing of up to 1 billion doses per year•  Technology transfer expected to begin in June 2020•  First...
23 Mar 2020
Lonza Launches New TheraPEAK™ SfAAV™ Medium to Boost and Optimize the Production of AAV in Sf9 Insect Cells
Lonza has launched a new medium to enhance and accelerate the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect...
20 Mar 2020
Lonza Joins the MIT Industrial Liaison Program
Lonza joins the MIT Industrial Liaison Program (ILP), gaining access to a vibrant ecosystem of research and technology development.Lonza’s...
09 Mar 2020
Lonza Collaborates with Immunotherapy Leaders to Assess Point-of-Care Manufacturing for Cancer Cell Therapies
Research collaboration with leading research institutes and academic clinical centers Stanford University School of Medicine, Fred Hutchinson...
19 Feb 2020
Lonza confirms COVID-19 case at Singapore General Office
Basel, Switzerland, 19 February 2020 –A Singapore-based employee of Lonza is being treated for a confirmed cased of COVID-19 (Coronavirus).Albert...
28 Jan 2020
Lonza Supporting Rocket Pharma with Clinical Manufacturing of LAD-I for the Treatment of Leukocyte Adhesion Deficiency-I
Clinical manufacturing to be carried out at Lonza's Houston (TX), USA and Geleen, Netherlands cGMP manufacturing sites for supply in the USA and in...
10 Jan 2020
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
•  Indapta developing first-in-class, proprietary cancer therapy based on a specific, potent variety of Natural Killer immune cells for use in...
09 Jan 2020
Lukas Schüpbach appointed CEO of Bacthera
Chr. Hansen and Lonza’s 50/50 joint venture for Live Biotherapeutic Products (LBP), Bacthera, announces Lukas Schüpbach as the company’s CEOBasel,...
19 Dec 2019
Lonza and Allevi Collaborate to Advance 3D Bioprinting
Collaboration brings technology and consumables together for bioprinting for research applications.Lonza brings a broad range of high-quality...
26 Nov 2019
Lonza and DiNAQOR AG Announce Strategic Collaboration to Advance Gene Therapy Programs for Patients with Monogenic Cardiomyopathies
Strategic collaboration to focus on DiNAQOR’s adeno-associated virus gene therapy production systemCompanies to partner on gene therapy process and...
13 Nov 2019
Lonza’s New eCHO™ Basal Medium and Feed Facilitates Late-Stage Cell Viability and a Consistent Yield of High Integrity Proteins
Lonza has launched a new basal and feed medium, specifically developed to drive significant viability and integrity enhancements in protein...
05 Nov 2019
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy
Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basisPartnership incorporates Cryoport’s...
16 Oct 2019
Mesoblast and Lonza Enter into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Therapy
Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza:“Mesoblast is a true trailblazer, leading the way in developing...
14 Oct 2019
Lonza’s Ibex™ Solutions to Support Genmab’s Growing Clinical Portfolio
Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 monthsLonza’s Ibex™ Develop will enable...
01 Oct 2019
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates
Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipelineManufacturing to take place at Lonza’s GMP site in Geleen,...
09 Sep 2019
Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiting Antibody CIT-013
•  Citryll’s CIT-013 could offer new treatment options for various human diseases including lupus, vasculitis, pulmonary fibrosis and organ damage...
03 Sep 2019
Celltrion and Lonza Sign Contract to Manufacture Remsima Drug Substance
•  Celltrion contracts Remsima drug substance manufacturing to Lonza to satisfy increasing global demand for biosimilars•  Lonza’s biologics...
29 Aug 2019
Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products
Copenhagen, Denmark and Basel, Switzerland, 29 August 2019 – Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading...
< 1 2 3 4 5 6 ... 9 >